Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -29.89% | -28.81% | -29.91% | -22.74% | -18.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.89% | -28.81% | -29.91% | -22.74% | -18.56% |
| Cost of Revenue | -47.35% | -48.69% | -50.79% | -50.02% | -11.76% |
| Gross Profit | 10.76% | 17.96% | 26.81% | 80.10% | -30.95% |
| SG&A Expenses | -32.22% | -37.63% | -38.44% | -29.65% | -22.86% |
| Depreciation & Amortization | 0.15% | 0.00% | 0.15% | 0.15% | 0.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.25% | -42.77% | -44.85% | -42.20% | -14.42% |
| Operating Income | 287.16% | 325.00% | 256.48% | 172.14% | -505.00% |
| Income Before Tax | 105.62% | 157.94% | 162.37% | 132.99% | 88.85% |
| Income Tax Expenses | -82.54% | -36.69% | -23.08% | 475.28% | 919.12% |
| Earnings from Continuing Operations | 93.47% | 127.60% | 136.35% | 123.76% | 76.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.47% | 127.60% | 136.35% | 123.76% | 76.72% |
| EBIT | 287.16% | 325.00% | 256.48% | 172.14% | -505.00% |
| EBITDA | 165.82% | 287.78% | 647.46% | 496.90% | -49.52% |
| EPS Basic | 93.33% | 126.18% | 135.32% | 123.23% | 76.89% |
| Normalized Basic EPS | 124.45% | 147.29% | 149.82% | 136.58% | 11.94% |
| EPS Diluted | 89.71% | 122.42% | 131.63% | 121.77% | 75.41% |
| Normalized Diluted EPS | 116.25% | 139.98% | 143.59% | 133.95% | 4.12% |
| Average Basic Shares Outstanding | -1.21% | 0.99% | 2.96% | 3.55% | 3.73% |
| Average Diluted Shares Outstanding | -0.05% | 2.70% | 4.66% | 6.14% | 6.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |